Notice of Website for Frequently asked questions (FAQs) about the Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) PAR-16-357

Notice Number: NOT-DA-17-044

Key Dates
Release Date: June 22, 2017

Related Announcements
 PAR-16-357

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

A hyperlink to Frequently Asked Questions (FAQs) Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) PAR-16-357 is provided to assist Early Stage Investigators (ESI) in applying for this funding opportunity announcement. The URL for the FAQ web page is https://www.drugabuse.gov/about-nida/organization/divisions/division-neuroscience-behavior-dnb/related-funding-opportunities.  The next deadlines for apply are October 19, 2017 and October 19, 2018 by 5:00PM local time of applicant organization.

The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.  These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction.  Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply.  The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309
Email: jpollock@mail.nih.gov